chevron_leftBack
As of 5 June 2026, PsyRX CNS Bio-Tech Ltd. has a market cap of $4.17M USD, ranking #45120 globally and #593 in Israel.
It ranks #3994 in the Healthcare sector, and #283 in the Drug Manufacturers - Specialty & Generic industry.
Key Stats
Market Cap
$4.17MUSD
12.05M ILS
Company Profile
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -4.1% | 1.4% | 5.7% | 23% | -36% | -69% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
CNTC
קנבוטק בע''מ
ISIN: IL0011769085
Shares Out.:
Shares Outstanding:
1.972M1
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
118 ILA |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About PsyRX CNS Bio-Tech Ltd.
PsyRX CNS Bio-Tech Ltd engages in developing cannabinoid-based medication and healthcare products. It provides drugs for various indications; personalized cannabinoid-based products; and CBD-based skincare and food-supplement products. PsyRX CNS Bio-Tech Ltd was formerly known as Cannabotech LTD. The company was incorporated in 2019 and is based in Rishon LeZion, Israel.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
TLV: TEVA
|
$37.66B
904K%
108.92B ILS
|
24.2
|
|
TLV: SEMG
|
$29.32M
604%
84.78M ILS
|
57.3
|
|
TLV: TGTR
|
$16.47M
295%
47.62M ILS
|
22.9
|
|
CSE: IMCC
|
$11.32M
172%
15.74M CAD
|
-
|
|
TLV: ALMD
|
$11.27M
171%
32.61M ILS
|
-
|
|
TLV: NXTG
|
$9.08M
118%
26.25M ILS
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: RVMD
|
$29.56B
710K%
|
-
|
|
SHE: 002001
|
$15.86B
381K%
107.34B CNY
|
16.0
|
|
NSE: CIPLA
|
$11.12B
267K%
1.06T INR
|
23.4
|
|
NSE: LUPIN
|
$11.0B
264K%
1.05T INR
|
22.7
|
|
SHE: 002653
|
$9.1B
218K%
61.6B CNY
|
80.6
|
|
EPA: ABVX
|
$8.78B
211K%
7.57B EUR
|
-
|
chevron_leftBack